Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
VBI Vaccines ( (VBIVQ) ) has shared an announcement.
VBI Vaccines Inc. has completed a restructuring process under the Companies’ Creditors Arrangement Act, resulting in the acquisition by K2 VBI Equity Trust, LLC. All common shares have been cancelled, and the company’s management has been replaced. VBI Vaccines plans to cease being a reporting issuer in Canada and deregister its shares in the U.S., impacting its disclosure obligations.
More about VBI Vaccines
VBI Vaccines Inc. is a biopharmaceutical company that develops vaccine candidates using innovative virus-like particles (VLP) technologies, including a proprietary enveloped VLP and mRNA-launched eVLP platform. The company is based in Cambridge, Massachusetts.
Average Trading Volume: 321,010
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $14.34K
For a thorough assessment of VBIVQ stock, go to TipRanks’ Stock Analysis page.